Praxis Precision Medicines switches auditor to KPMG from EY

Praxis Precision Medicines has dismissed Ernst & Young as its independent auditor, effective June 29, 2026. The company engaged KPMG to replace EY on the same date. Both firms reported no adverse opinions or reportable disagreements regarding accounting, disclosure, or audit scope for fiscal years 2024 and 2025.

Praxis Precision Medicines dismissed Ernst & Young as independent auditor effective June 29, 2026. * EY audit reports for fiscal 2025 and 2024 carried no adverse opinion, disclaimer, or qualifications. * No reportable disagreements with EY on accounting, disclosure, or audit scope through June 29, 2026. * KPMG was engaged as the new independent auditor, effective the same day. * No consultations with KPMG on specific accounting treatments or potential audit opinions during fiscal 2025 and 2024 through June 29, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080356), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Praxis Precision Medicines dismissed Ernst & Young as independent auditor effective June 29, 2026. * EY audit reports for fiscal 2025 and 2024 carried no adverse opinion, disclaimer, or qualifications. * No reportable disagreements with EY on accounting, disclosure, or audit scope through June 29, 2026. * KPMG was engaged as the new independent auditor, effective the same day. * No consultations with KPMG on specific accounting treatments or potential audit opinions during fiscal 2025 and 2024 through June 29, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080356), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here